Ballot Measure 109, passed by Oregon voters in 2020, established the nation’s first regulatory framework for psilocybin services. Now codified as ORS 475A, the measure set a two-year development period from January 1, 2021, to December 31, 2022. This groundbreaking measure came in response to Oregon’s high rates of mental illness, with about one in five residents suffering from a mental health condition. Recognizing the severity of the crisis, the Governor declared a public health emergency and allocated over $2.8 billion for mental and behavioral health programs in the 2019-2021 budget.
Research from prominent medical institutions has demonstrated that psilocybin may be an effective, safe, and well-tolerated treatment for various mental health issues, including addiction, depression, anxiety disorders, PTSD, and end-of-life distress. In recognition of its potential, the FDA designated psilocybin as a Breakthrough Therapy for treatment-resistant depression. The Oregon Health Authority (OHA) is now tasked with overseeing research, public education, and the creation of a regulatory framework for psilocybin services, which are available to adults aged 21 and older.
During the development period, Oregon counties were given the option to either opt in or out of permitting psilocybin treatment clinics. In Josephine County, for instance, the decision was placed before voters, while in the City of Grants Pass, elected officials made the call. A key question remains: how well did citizens and community leaders understand psilocybin when making their decisions? With so much more information available today than two years ago, one might wonder whether some residents would have voted differently, especially given the growing emphasis on functional medicine and “Making America Healthy Again.”
Psilocybin comes in several forms. Most commonly, it is found in mushrooms, primarily from the Psilocybe genus, though other types, such as Panaeolus, also contain psilocybin. Additionally, other sources of psilocybin, such as the Iboga plant and the venom of certain toads, provide different compounds like ibogaine and 5MeO-DMT. Many of these substances are now synthesized for medical use.
Recent studies indicate that psilocybin-based medicines can help treat a wide variety of health issues, including depression, addiction, PTSD, anxiety, and chronic pain. Ongoing research from institutions like the National Institutes of Health (NIH), Stanford, and Johns Hopkins has shown promising results in treating not just mental health conditions, but also physical ailments such as Parkinson’s disease, multiple sclerosis, and traumatic brain injury (TBI). Clinical studies both in the U.S. and abroad track patients before and after treatment to assess the effectiveness of these therapies, and the results have been positive.
Several U.S. states, including Oregon, Colorado, Michigan, Minnesota, California, and Washington, have decriminalized psilocybin to varying extents. However, not all states have embraced substances like ibogaine or ketamine, which are classified as Schedule I and Schedule III non-narcotic substances, respectively. Ketamine, widely used in hospital settings for pain management, is also employed to treat conditions like fibromyalgia, cancer pain, and headaches.
Psilocybin treatments are typically administered in a clinical setting, where patients can be monitored throughout the process. Clinics across the U.S. and abroad offer psilocybin-assisted therapies, including the use of mushrooms, ashwagandha, and ayahuasca, with patients traveling to places like Mexico, Costa Rica, Peru, and Germany for ibogaine treatment. Since ibogaine can present risks to heart health, clinics often conduct thorough monitoring, supplement the body with vitamins, and provide hydration before treatment to ensure patient safety.
The benefits of psilocybin medicines are wide-ranging. Many patients experience life-changing results, such as overcoming addiction, finding peace from PTSD, alleviating chronic pain, and even managing symptoms of conditions like MS and Parkinson’s disease. These treatments may even help patients reduce or eliminate their reliance on mainstream pharmaceuticals, which often come with undesirable side effects.
Despite growing research and anecdotal evidence supporting the benefits of psilocybin, the looming question remains: should all psilocybin treatments be allowed in the U.S.? And why is research conducted outside the U.S. necessary for respected institutions to study their effects? In the November 2022 General Election, Josephine County voters decided to reject a local measure that would have allowed psilocybin manufacturing and service centers in the county. In contrast, the Grants Pass City Council passed an ordinance on January 4, 2023, to permit such centers within the city limits. One city councilor even questioned whether citizens were fully educated on the issue when making their decision, which raises an important point.
Psilocybin treatments have shown significant potential to improve the quality of life for many, especially veterans, first responders, and survivors of traumatic experiences. While these treatments can be costly, non-profit organizations across the country offer financial assistance to patients. Furthermore, for those who struggle with conventional pharmaceuticals, psilocybin treatments offer an alternative that could help eliminate or reduce their reliance on medications that often have harmful side effects. Additionally, psilocybin can help prevent suicide and alleviate suicidal ideations, potentially saving lives.
Though some may fear that these medicines could be addictive, studies suggest they are not. Personally, an ibogaine journey is a profound and intense experience that many patients do not wish to repeat frequently. Those curious about the potential healing effects of these medicines can explore options like ibogaine treatment at international clinics, or ketamine treatments available in several U.S. states, including locations in Medford, OR. These treatments may hold the key to a brighter, healthier future for thousands of individuals in need.